Cargando…

Mutual regulation between CHD5 and EZH2 in hepatocellular carcinoma

Chromodomain helicase DNA binding protein 5 (CHD5) acts as a tumor suppressor in many cancers. In the present study, we demonstrated that reduced levels of CHD5 in hepatocellular carcinoma (HCC) tissues were significantly associated with metastasis and poor prognosis. Gain-of-function assays reveale...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Cheng-Rong, Li, Zhao, Sun, Hong-Guang, Wang, Fu-Qiang, Sun, Yu, Zhao, Wen-Xiu, Zhang, Sheng, Zhao, Wen-Xing, Wang, Xiao-Min, Yin, Zhen-Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747380/ https://www.ncbi.nlm.nih.gov/pubmed/26517514

Ejemplares similares

Significance of genetic variants in DLC1 and their association with hepatocellular carcinoma
por: XIE, CHENG-RONG, et al.
Publicado: (2015)

The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinoma
por: Wu, Shi-yi, et al.
Publicado: (2022)

miR-454 functions as an oncogene by inhibiting CHD5 in hepatocellular carcinoma
por: Yu, Lei, et al.
Publicado: (2015)

Natural killer cells inhibit pulmonary metastasis of hepatocellular carcinoma in nude mice
por: HONG, ZAI-FA, et al.
Publicado: (2016)

Integrated analysis of gene expression and DNA methylation changes induced by hepatocyte growth factor in human hepatocytes
por: XIE, CHENG-RONG, et al.
Publicado: (2015)

The single-nucleotide polymorphisms in CHD5 affect the prognosis of patients with hepatocellular carcinoma
por: Zhu, Xiao, et al.
Publicado: (2017)

Distinct binding pattern of EZH2 and JARID2 on RNAs and DNAs in hepatocellular carcinoma development
por: Wen, Zhili, et al.
Publicado: (2022)

EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma
por: Xiao, Gang, et al.
Publicado: (2019)

Decreased expression of ARID1A associates with poor prognosis and promotes metastases of hepatocellular carcinoma
por: He, Fei, et al.
Publicado: (2015)

Long Noncoding RNA HCAL Facilitates the Growth and Metastasis of Hepatocellular Carcinoma by Acting as a ceRNA of LAPTM4B
por: Xie, Cheng-Rong, et al.
Publicado: (2017)

Effects of EZH2 Polymorphisms on Susceptibility to and Pathological Development of Hepatocellular Carcinoma
por: Yu, Yung-Luen, et al.
Publicado: (2013)

Analysis on EZH2: mechanism identification of related CeRNA and its immunoassay in hepatocellular carcinoma
por: Zhao, Haoran, et al.
Publicado: (2023)

EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies
por: Wang, Bohan, et al.
Publicado: (2023)

Expression of Hcy and blood lipid levels in serum of CHD patients and analysis of risk factors for CHD
por: Liu, Weijing, et al.
Publicado: (2019)

Cantharidin suppresses hepatocellular carcinoma development by regulating EZH2/H3K27me3-dependent cell cycle progression and antitumour immune response
por: Yan, Jia, et al.
Publicado: (2023)

EZH2 Expression is increased in BAP1-mutant renal clear cell carcinoma and is related to poor prognosis
por: Sun, Chenmin, et al.
Publicado: (2018)

Upregulation of the ErbB family by EZH2 in hepatocellular carcinoma confers resistance to FGFR inhibitor
por: Prawira, Aldo, et al.
Publicado: (2021)

CHD1 deletion stabilizes HIF1α to promote angiogenesis and glycolysis in prostate cancer
por: Wang, Yu-Zhao, et al.
Publicado: (2023)

LINC01419 facilitates hepatocellular carcinoma growth and metastasis through targeting EZH2-regulated RECK
por: Zhang, Gong, et al.
Publicado: (2020)

ADNP Controls Gene Expression Through Local Chromatin Architecture by Association With BRG1 and CHD4
por: Sun, XiaoYun, et al.
Publicado: (2020)

Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells
por: Zhen, Mao-Chuan, et al.
Publicado: (2016)

CHD4 variants are associated with childhood idiopathic epilepsy with sinus arrhythmia
por: Liu, Xiao‐Rong, et al.
Publicado: (2021)

CHD1L augments autophagy-mediated migration of hepatocellular carcinoma through targeting ZKSCAN3
por: Zhang, Xiaofeng, et al.
Publicado: (2021)

The epigenetic factor CHD4 contributes to metastasis by regulating the EZH2/β-catenin axis and acts as a therapeutic target in ovarian cancer
por: Wang, Jieyu, et al.
Publicado: (2023)

CHD1L Is a Marker for Poor Prognosis of Hepatocellular Carcinoma after Surgical Resection
por: Hyeon, Jiyeon, et al.
Publicado: (2013)

Silencing of CHD5 Gene by Promoter Methylation in Leukemia
por: Zhao, Rui, et al.
Publicado: (2014)

Overexpression of CHD1L is associated with poor survival and aggressive tumor biology in esophageal carcinoma
por: Liu, Ze-Han, et al.
Publicado: (2017)

Apigenin inhibits NF-κB and Snail signaling, EMT and metastasis in human hepatocellular carcinoma
por: Qin, Yuan, et al.
Publicado: (2016)

The Expression Significance of LPa, BNP, and McP-1 in CHD Patients and Their Relationship with Echocardiographic Parameters
por: Ma, Yunpeng, et al.
Publicado: (2022)

An In Vivo and In Vitro Evaluation of the Mutual Interactions between the Lung and the Large Intestine
por: Yin, Lei-Miao, et al.
Publicado: (2013)

EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis
por: Chen, Shaofei, et al.
Publicado: (2018)

Oligodendrocyte precursor survival and differentiation requires chromatin remodeling by Chd7 and Chd8
por: Marie, Corentine, et al.
Publicado: (2018)

EZH2/H3K27Me3 and phosphorylated EZH2 predict chemotherapy response and prognosis in ovarian cancer
por: Sun, Si, et al.
Publicado: (2020)

Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma
por: Sudo, T, et al.
Publicado: (2005)

EZH2 is a negative prognostic biomarker associated with immunosuppression in hepatocellular carcinoma
por: Guo, Baoping, et al.
Publicado: (2020)

Clinical Value of EZH2 in Hepatocellular Carcinoma and Its Potential for Target Therapy
por: Bae, An-Na, et al.
Publicado: (2022)

Inhibition of Snail Family Transcriptional Repressor 2 (SNAI2) Enhances Multidrug Resistance of Hepatocellular Carcinoma Cells
por: Zhao, Xin-Yu, et al.
Publicado: (2016)

FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling
por: Yang, Yiqi, et al.
Publicado: (2023)

Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2
por: Zhang, Dong-Yan, et al.
Publicado: (2020)

Red-light is an environmental effector for mutualism between begomovirus and its vector whitefly
por: Zhao, Pingzhi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rj9ompjjj376etteskphofhduf